Candel Therapeutics presents ASTRO 2026 prostate cancer data
Candel Therapeutics said new data at ASTRO 2026 showed sustained immune remodeling more than two years after aglatimagene besadenovec treatment in localized prostate cancer.
Candel Therapeutics said new data at ASTRO 2026 showed sustained immune remodeling more than two years after aglatimagene besadenovec treatment in localized prostate cancer.